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In the context of kidney transplantation, little is known about the involvement of natural
killer (NK) cells in the immune reaction leading to either rejection or immunological toler-
ance under immunosuppression. Therefore, the peripheral NK cell repertoire of patients
after kidney transplantation was investigated in order to identify NK cell subsets that may
be associated with the individual immune status at the time of their protocol biopsies
for histopathological evaluation of the graft. Alterations in the peripheral NK cell reper-
toire could be correlated to the type of immunosuppression, i.e., calcineurin-inhibitors
like Cyclosporin A vs. Tacrolimus with or without addition of mTOR inhibitors. Here, we
could demonstrate that the NK cell repertoire in peripheral blood of kidney transplant
patients differs significantly from healthy individuals. The presence of donor-specific anti-
bodies was associated with reduced numbers of CD56dim NK cells. Moreover, in patients,
down-modulation of CD16 and CD6 on CD56dim NK cells was observed with significant
differences between Cyclosporin A- and Tac-treated patients. Tac-treatment was associ-
ated with decreased CD69, HLA-DR, and increased CD94/NKG2A expression in CD56dim
NK cells indicating that the quality of the immunosuppressive treatment impinges on the
peripheral NK cell repertoire. In vitro studies with peripheral blood mononuclear cells of
healthy donors showed that this modulation of CD16, CD6, CD69, and HLA-DR could
also be induced experimentally. The presence of calcineurin or mTOR inhibitors had also
functional consequences regarding degranulation and interferon-γ-production against K562
target cells, respectively. In summary, we postulate that the NK cell composition in periph-
eral blood of kidney transplanted patients represents an important hallmark of the efficacy
of immunosuppression and may be even informative for the immune status after trans-
plantation in terms of rejection vs. drug-induced allograft tolerance. Thus, NK cells can
serve as sensors for immunosuppression and may be utilized for future strategies of an
individualized adjustment of immunosuppression.
Keywords: NK cells, cytotoxicity, cytokine secretion, kidney transplantation, immunosuppression,
calcineurin-inhibitors, mTOR inhibitors, donor-specific antibodies
INTRODUCTION
Human natural killer (NK) cells are part of the innate immune
system and play a critical role in the host defense against pathogens
and tumor cells by their cytotoxic potential and the production of
cytokines and chemokines. Based on the cell surface density of
the CD56 molecule, human peripheral NK cells can be divided
Abbreviations: ABMR, antibody-mediated rejection; CNI, calcineurin inhibitor;
CsA, Cyclosporin A; DSA, donor-specific antibodies; HLA, human leukocyte anti-
gen; IS, immunosuppression; KIR, killer-immunoglobulin-like receptors; KTx,
kidney transplantation; MMF, mycophenolate mofetil; MPA, mycophenolic acid;
mTORi, mammalian target of rapamycin (mTOR) inhibitor; NK cells, natural killer
cells; Sir, sirolimus; Tac, Tacrolimus; Tx, transplantation.
into two major subsets (CD56dim and CD56bright), with each
group displaying distinct phenotypic and functional properties.
The markers include the Fcγ-receptor IIIa (CD16), CD6 (Braun
et al., 2011), and KIR (killer cell immunoglobulin-like receptors)
which are expressed on the majority of CD56dim cells. In con-
trast to the CD56dim subset, CD56bright NK cells express CD16
and CD6 at very low levels of less than 3% but display a higher
density of the inhibitory heterodimer CD94/NKG2A (Yu et al.,
2010). Other surface receptors such as the activation-dependent
markers CD25, CD69, HLA-DR, and typical NK cell receptors like
the natural cytotoxicity receptors (NCR), NKG2D, and CD161
are equally expressed on both subsets. In addition to the distinct
phenotypic features, the two NK cell subsets are also associated
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with different effector functions. It is generally accepted that naïve
CD56dim NK cells are primarily responsible for cytotoxic activity
due to their high content of granules filled with cytotoxins like
perforin, granzyme A, and B. In contrast, CD56bright NK cells
are postulated to regulate immune responses primarily through
their cytokine production, for example by secretion of interferon
(IFN)-γ after stimulation with interleukin (IL)-2, IL-12, or IL-15.
Natural killer cells were recently discussed to be involved in
immune recognition after kidney transplantation due to their
capability to bind donor-specific anti-HLA-antibodies (donor-
specific Ab, DSA) (Farkash and Colvin, 2012). However, the
peripheral NK cell repertoire of kidney recipients has not been
studied in great detail and the influence of different immunosup-
pressive regimens like calcineurin (CNI) or mTOR inhibitors on
NK cell subset distribution has not been precisely addressed.
Since many years, it is known that DSA have a negative impact
on survival and function of kidney transplants (Halloran et al.,
1990, 1992; Lucas et al., 2011). Anti-HLA-Ab can be induced in
the context of kidney transplantation based on HLA class I- and/or
class II mismatches between donor and recipient. Acute antibody-
mediated rejection (ABMR) is pathologically characterized by
glomerulitis, peritubular capillaritis, dilatation of peritubular cap-
illaries, and interstitial edema (Lefaucheur et al., 2007; Loupy et al.,
2009). Acute ABMR occurs within days to weeks after transplanta-
tion and is primarily caused by de novo-synthesized DSA. Chronic
ABMR presents with duplication of the glomerular and/or mul-
tilayering of the peritubular capillary basement membrane and
possibly with chronic lesions as interstitial fibrosis and tubular
atrophy or fibrous intimal thickening of arteries in combination
with the presence of anti-HLA-Abs, especially DSA (Liefeldt et al.,
2012). One proposed mechanism of these antibodies is activation
of complement that can be measured by staining of C4d, a cleavage
product of the activated C4 component of the classical comple-
ment pathway (Mengel et al., 2012). Recent work by Terasaki et al.
has clearly identified DSA as the major cause of chronic rejection
(Terasaki and Cai, 2008; Hidalgo et al., 2010). Since HLA class I-
and II-antigens are differentially expressed on immune and non-
immune cells, DSA against HLA class I- or II-molecules generate
diverse pathological effects in the transplant. While HLA class I
specific DSA are more responsible for rapid graft loss, HLA class II
specific DSA rather seem to cause chronic rejection (Worthington
et al., 2003). Besides HLA-specific antibodies, an involvement of
antibodies directed against two polymorphic ligands for the T and
NK cell receptor NKG2D, i.e., MICA and MICB, in declining graft
function is still controversially discussed (Zou et al., 2007).
The current concept of initial immunosuppression by CNI after
kidney transplantation is focused on the suppression of T cell-
mediated immune reactions toward the allogeneic organ which is
matched for as many as possible HLA class I (A and B) and class
II (DR) antigens. Although HLA-C molecules represent promi-
nent KIR ligands, HLA-C typing is not routinely performed and
rather ignored along with HLA-DQ and HLA-DP molecules for
the allocation of kidneys from deceased donors to renal insufficient
patients. The standard immunosuppressive regimen, also at our
transplantation unit is based on initial CNI, either cyclosporine
A (CsA) or Tacrolimus (Tac) in combination with steroids (pred-
nisolone) and mycophenolate mofetil (MMF) (Heemann et al.,
2011). Once treated with this CNI-based regimen, minimization
of the drug is associated with a higher risk of rejection. Operational
tolerance is defined as a “well-functioning graft lacking histologi-
cal signs of rejection in the absence of immunosuppressive drugs
for at least 1 year in an immune-competent host” (Ashton-Chess
et al., 2007; Orlando et al., 2010). Spontaneous tolerance after
complete withdrawal of immunosuppression is rare after kidney
transplantation. Clinical attempts to induce operational tolerance
by different concepts for long-term adaptation of the recipient
immune system for an allogeneic organ were not successful so far
(Page et al., 2012). Current strategies focus on the identification
of tolerance markers under maintained immunosuppression that
define a status of “organ acceptance” which supports long-term
graft function and survival (Orlando et al., 2010). This clini-
cally relevant “tolerance status” under immunosuppression may
be mediated by both adaptive and innate immune cells although
this hypothesis has not been proven yet. In tissue biopsies and
periphery blood of kidney recipients, NK cell signatures have been
recognized in tolerant states (Sagoo et al., 2010) as well as in ABMR
(Hidalgo et al., 2010). However, the role of NK cell subsets in this
context has not been investigated in detail, especially not in light
of different immunosuppressive drugs.
In general, CNI-based immunosuppressive therapies with CsA
in combination with steroids and MMF are frequently associ-
ated with nephrotoxicity in the graft favoring a development of
interstitial fibrosis and tubular atrophy and, on the long run, a
decrease in kidney function or even graft loss (Casey and Meier-
Kriesche, 2011). Compared to CsA, Tac is suggested to have a
lower grade of nephrotoxicity due to its higher immunosuppres-
sive potential even at lower drug concentrations which correlates
with lower trough levels that are routinely measured 12 h after
medication in serum of kidney Tx patients (Ekberg et al., 2007).
This effect is not completely depending on the substance itself but
also on interactions with co-medication, e.g., MMF. In Tac-treated
patients, effective MMF levels are higher since the depressing effect
of cyclosporine on the enterohepatic recirculation of mycopheno-
late is missing (Kuypers, 2008). Thus, a switch from CsA to Tac
represents one possibility to reduce CNI toxicity. Another possibil-
ity to minimize nephrotoxicity is an immunosuppressive therapy
with mTORi (e.g., sirolimus/Sir or everolimus). Several studies
demonstrated that complete withdrawal of CNI after switching to
mTORi is clinically safe at least up to 12 months post transplan-
tation (Budde et al., 2011). CNI primarily inhibit T cell activation
due to a block in signal transduction at the NFAT-binding pro-
tein FKPB12 which prevents transcriptional activation via NFAT
and expression of its downstream targets like IL-2, IFN-γ, GM-
CSF, and others. In contrast, mTORi block signal transduction of
the PI3K/Akt pathway in immune as well as in non-immune cells.
While both pathways were studied extensively in T cells as primary
target cells of CNI, only limited information is available on the
effect of CNI vs. a combination with mTORi on the composition
of NK cell subsets in patients after kidney transplantation.
Recent in vitro studies have shown differential effects of
immunosuppressive drugs on NK cells derived from healthy
donors. Treatment of sorted CD56bright and CD56dim NK cells fol-
lowing IL-2 and IL-15 stimulation with immunosuppressive drugs
resulted in a more pronounced shift toward the CD56bright subset
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and KIR/NKG2A expression by the mTORi rapamycin and MPA
compared to CsA (Eissens et al., 2010). These phenotypic changes
were accompanied by impaired proliferation and cytotoxicity in
rapamycin- and MPA-treated NK cells and reduced IFN-γ secre-
tion also by CsA treatment. Similar effects of Tac compared to CsA
were demonstrated regarding expansion and phenotypic alter-
ations of IL-2/IL-15-activated purified NK cells of healthy donors
(Ohata et al., 2011). These investigations indicate a differential
influence of immunosuppressive drugs on the composition of NK
cell subsets and their functional status, i.e., cytokine production
and cytotoxicity.
In our study, we investigated peripheral NK cell subsets in kid-
ney transplanted patients in correlation to the individual immuno-
suppressive regimen and the presence of donor-specific antibodies.
In addition, we determined the effect of CNI and mTORi on
NK cell functions like IL-2-mediated activation, IFN-γ secretion
and degranulation in vitro in healthy donors. The presence of
DSA in kidney recipients was associated with reduced numbers
of CD56dim NK cells in peripheral blood. Moreover, the periph-
eral NK cell repertoire of patients after kidney transplantation was
significantly altered compared to healthy donors by a significant
decrease in CD16+ CD6+ CD56dim NK cells. Remarkably, the type
of immunosuppression, CsA vs. Tac, had a strong impact on the
NK cell phenotype with increased CD69+ NK cells in patients
under CsA vs. Tac-mediated immunosuppression. These effects in
patient blood could also be observed by in vitro treatment of NK
cells from healthy donors with immunosuppressive drugs. How-
ever, it needs to be further investigated whether the loss of CD16
and CD6 expression may represent rather a sign of NK cell activa-
tion or functional exhaustion. In summary, we could demonstrate
that the NK cell repertoire is altered in kidney recipients accord-
ing to the individual immunosuppression suggesting that NK cells
may serve as sensors of immunosuppression.
MATERIALS AND METHODS
PATIENTS AND HEALTHY DONORS
The collection of blood from patients and healthy donors was
approved by the ethics committee at University of Heidelberg, no.
S-163/2007, as well as by the ethics committee of Hannover Med-
ical School, no. 968-2011, and kidney recipients gave informed
consent on the basis of the ethics vote no. 5970. One hundred
twenty-four kidney transplanted patients were enrolled into this
study within 2011 and 2012. The cohort had 49 male and 75 female
patients, aged 49.56 years± 14.83 (SD), with a kidney transplant
age of 46.19 months± 16.07 (SD). Regarding immunosuppres-
sion, 30 patients received CsA, 78 tacrolimus (Tac group), and 16
tacrolimus in combination with the mTORi, Sir, or everolimus
(T/S group). While CsA and Tac-treated patients also receive
MMF and steroids (Prednisolon), no MMF is given to patients
with low CNI+mTORi (T/S). Peripheral blood mononuclear cells
(PBMC) from patients were taken at the time of their protocol
biopsy at ≤1 month (n= 30), 3 (n= 30), 6 (n= 24), 9 (n= 3),
or ≥12 (n= 37) months after transplantation. From these 124
patients, 18 were preselected for this NK cell subset analyses based
on the histopathological classification of the kidney biopsy at the
day of blood withdrawal: unsuspicious histology, T cell-mediated
rejection (TCMR), ABMR, and borderline pathology. Regarding
immunosuppression, 5 patients were in the CsA, 10 patients in the
Tac, and 3 patients in the low-dose CNI+mTORi (T/S) group.
Since the patient material is limited by the informed consent,
it was not possible to perform these subset analyses with blood
from all patients. As normal control samples, PBMC of healthy
age-matched volunteers (n= 21) where compared to the kidney
recipients.
PHENOTYPIC CHARACTERIZATION AND ABSOLUTE NUMBERS OF NK
CELL SUBSETS
Peripheral blood mononuclear cells from patients and healthy
donors where separated using Ficoll (Biochrom, Berlin, Germany)
separation. The following mAbs were used for cell surface staining
by multi-color flow cytometry: CD3-PerCP (clone SK7), CD94-
FITC (clone HP3D9), HLA-DR-APC (clone G46-6; BD, Franklin
Lakes, NJ, USA), CD56-ECD (clone N901), NKG2A-PE (clone
Z199), CD69-PE (clone TP1.55.3), CD25-FITC (clone M-A251),
CD16-FITC (clone 3G8; Beckman Coulter, Krefeld, Germany),
CD161-PerCP-Cy5.5 (clone HP-3G10,eBioscience, San Diego, CA,
USA), and CD6-APC (clone MT411, Miltenyi Biotec, Auburn,
CA, USA). PBMC were incubated with mAbs for 30 min at 4˚C,
washed with PBS (Life Technologies, NY, USA) with 2.5% FBS
(Life Technologies) and 0.1% sodium azide (Sigma-Aldrich, St.
Louis, MO, USA) and fixed with PBS containing 1% paraformalde-
hyde (Merck, Darmstadt, Germany). Cells were analyzed by flow
cytometry (LSRII, BD), Data were processed using FACS-Diva
software 6.1.2 (BD). Absolute lymphocyte numbers (e.g., CD56+
NK cells) per µl of peripheral blood where determined via Tru-
count™(BD) analysis using 50µl EDTA blood and fluorochrome-
labeled mAb for CD56 (PE)+CD16 (PE) with a known number
of beads. Absolute NK cell numbers per µl were calculated by
counting CD3− CD56/CD16+ events and normalization to beads
using the formula: absolute NK cell count per µl= (number of
events in cell population/number of events in absolute count bead
region)× (number of known beads per test/test volume).
IDENTIFICATION OF ALLO-HLA, DONOR-SPECIFIC, AND MICA-SPECIFIC
ANTIBODIES
Serum samples were collected at the same points of time as proto-
col biopsies. The presence of anti-HLA-antibodies as well as MICA
antibodies in all patient sera was detected by using the Luminex-
based LABScreen-Mixed-Assay (One Lambda, Canoga Park, CA,
USA). All samples that were unambiguously positive for anti-
HLA class I and/or class II antibodies (MFI> 1000) were further
tested for DSA using the LABScreen Single Antigen beads (One
Lambda). All tests were performed according to the manufacturer’s
guidelines.
IN VITRO ANALYSES OF THE EFFECT OF CNI, mTORi, AND MMF ON
ACTIVATION AND PROLIFERATION, DEGRANULATION, AND IFN-γ
ELISpot ASSAYS
The influence of immunosuppressive drugs on NK cell func-
tion was analyzed in vitro by proliferation, degranulation, and
IFN-γ ELISpot assays using PBMC from healthy individuals. For
the activation assay, 1× 105 PBMC were incubated for 4 days in
RPMI1640 (Invitrogen) supplemented with 2 mM l-glutamine,
1 mM sodium pyruvate, 100 U/ml penicillin/streptomycin, and
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10% fetal calf serum (FCS, Invitrogen) in the presence or absence
of IL-2 (500 U/ml) with or without 10µM of either CsA, Tac,
Sir (all three LC Laboratories, Woburn, MA, USA), MMF (Sell-
eckchem, Houston, TX, USA), or equal concentrations of DMSO
(Carl Roth, Karlsruhe, Germany). The cells were harvested,
washed once in PBS and stained with CD25-FITC, CD69-PE,
CD56-ECD, CD3-PerCP, and CD16-Pacific Blue Ab as described
above.
CD107a-Degranulation assays were performed with plate
bound mAbs against CD16 (clone 3G8, Beckmann Coulter) or
the isotype control IgG1 (clone MOPC21, Sigma) in a 96 well U-
shaped plate (BD). Goat-anti-mouse-F(ab)2 (Beckman Coulter)
was coated over night with 2µg/ml in boracid containing buffer
(0.05 M, pH 8.6). After washing twice with PBS, mAbs (10µg/ml
in PBS) were coated for 1 h at 4˚C. The plate was washed twice
with PBS, 2.5× 105 PBMC were incubated for 4 h in RPMI 1640
supplemented with 2 mM l-Glutamine, 1 mM Sodium Pyruvate,
100 U/ml Penicillin/Streptomycin, and 10% FCS with or without
10µM of either of the drugs or the solvent DMSO in the presence
of anti-CD107a-PE-Ab (clone H4A3, BD). After 1 h incubation,
Monensin (40µM, Sigma) was added. Cells were harvested after
4 h, once washed in PBS and stained with CD3-PerCP, CD56-ECD,
and CD16-FITC Ab as described above.
For the IFN-γ-ELISpot, the “human IFN-γ ELISPOT antibody
pair” (detection and capture anti-IFN-γAb, BD) was used. The
assay was performed according to the manufacturer’s instructions
except for the use of the alkaline phosphatase-streptavidin (BD)
for binding to the biotinylated anti-IFN-γ detection Ab. For detec-
tion of IFN-γ spots, the AP-conjugated substrate kit (Bio-Rad,
Hercules, CA, USA) was used. PBMCs of healthy donors (n= 3)
were stimulated in the presence of the HLA-negative target cell
line K562 with a ratio of 3:1 respectively 1:1 (PBMC cell num-
bers were donor-dependent either 6/2× 105 or 3/1× 105 per well)
in triplicates and two titrations as recommended by CIMT. The
stimulation was performed for 18 h in RPMI 1640 supplemented
with 2 mM l-glutamine, 1 mM sodium pyruvate, 100 U/ml peni-
cillin/streptomycin, and 10% FCS with or without 10µM of either
drug or DMSO solvent.
The number of IFN-γ producing NK cells was determined by
capturing IFN-γ to the plate and detection by the biotinylated
mAb. Immunospots were quantified by the Immunospot S5 UV-
Reader (CTL, Shaker Heights, OH, USA); plates were scanned by
Immunospot 5.0-Software (CTL) and the data were analyzed by
the Immunospot 5.1 professional software (CTL).
For the proliferation assay, PBMC of four healthy donors were
labeled with eFluor 670 (eBioscience,Frankfurt,Germany) accord-
ing to the manufactures protocol. EFluor 670 binds to cellular
proteins and during cell division the dye is distributed equally to
the divided cells. 2× 105 eFluor labeled PBMC where incubated
either alone or in the presence of 1× 105 HLA class I-negative
K562 cells (irradiated with 100 Gy) in absence or presence of
DMSO, CsA, Tac, Sir, or MMF (each with 10µM) in a 96 well
U-shaped plate (BD). After 48 and 96 h, respectively, cells were
harvested, washed once in PBS, and stained with CD3-PerCP and
CD56-ECD Ab as described above and analyzed by flow cytometry
gating on CD3− CD56+ eFluor 670low cells as % of proliferating
NK cells.
Statistics
All statistical calculations were performed with the GraphPad
Prism 5.01 program (La Jolla, CA, USA). The sample values
and replicates, respectively, were applied first to three normality
tests, Komolgorov–Smirnov, D’Agostino–Pearson, and Shapiro–
Wilk followed by either t -tests for Gaussian distributed data or
Mann–Whitney U -tests for non-parametric data sets.
RESULTS
THE PERIPHERAL NK CELL REPERTOIRE OF KIDNEY TRANSPLANT
RECIPIENTS IS INFLUENCED BY DSA AND THE TYPE OF
IMMUNOSUPPRESSION
The distribution of the two major NK subsets, CD56dim, and
CD56bright NK cells is rather stable in peripheral blood of healthy
volunteers. In order to identify an influence of DSA and the
immunosuppressive regimen on NK cells in kidney transplanted
patients, the number and subset distribution of NK cells were ana-
lyzed in 120 kidney recipients (KTx) at <1, 3, 6, and 12 months
(n= 86) and >12 months (n= 34) after transplantation. Regard-
ing the percentage of NK cells in the lymphocyte population, no
significant differences could be observed between KTx-patients
either in the group between 1 and 12 months or in the group
>12 months after transplantation and healthy volunteers (n= 21;
Figure 1A). For the determination of NK cell numbers per µl,
the Trucount staining procedure was performed in which NK cells
are marked by CD56 PE and CD16 PE antibodies in combination
with T and B cell markers. This NK cell staining combination was
developed for routine FACS staining of whole blood and, thus, can-
not be changed without leaving the approved protocol for clinical
immunology. In order to discriminate between the CD56bright and
CD56dim NK cell subsets despite simultaneous CD16 staining, his-
togram analyses of the CD16/CD56 PE-staining were performed
as indicated by the three boxes in Figure 1C. In healthy donors,
the combined CD16/CD56 staining nicely reflected the CD56dim
and CD56bright single staining (data not shown). In KTx-patients,
an additional NK cell subset with markedly reduced CD16/CD56
density was detectable that was defined as CD56/16low subset
(Figure 1C). Thus, NK cells were divided into three subsets, i.e.,
CD56/16bright, CD56/16dim, and CD56/16low, for all Trucount
analyses and the subset distribution as well as the number per
µl blood were determined. The CD56/16low NK cell subset was
detectable in all KTx-patients and the amount ranged from 1.9
to 54.3% of NK cells (2–263 cells per µl blood, Figure 1B). Since
CD56 and CD16 are both stained with PE-labeled mAb in this rou-
tine FACS combination, it was not possible to assign this decreased
expression to the CD56 or CD16 surface molecule. Therefore, sin-
gle staining analyses were performed demonstrating that the CD56
histograms displayed the typical CD56bright and CD56dim densities
with some individual variation in the proportion of the two sub-
sets. However, the CD16 histograms clearly discriminated between
those patients with a high proportion of CD16+NK cells and those
patients with CD16 down-regulation. Thus, we hypothesized that
the CD56/16low phenotype resulted from decreased CD16 surface
expression which was further investigated in detail by a cohort of
18 patients (Figure 4). An influence of the time after KTx on NK
cell distribution could be excluded since the division into patients
< or>12 months after Tx displayed only minor differences. Only
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FIGURE 1 | Distribution of NK cells shows marginal differences between
kidney transplanted patients (KTx) and healthy donors. Proportion and
absolute number of CD56+ CD3− NK cells were compared between
KTx-patients (n=120, white boxes) and healthy donors (n=21, gray boxes)
using the standardized Trucount™ FACS analysis. (A) KTx-patients were
divided into two groups according to the time after transplantation (group
1<12 and group 2>12 months after Tx) and the percentage of NK cells was
compared to healthy donors. (B) NK cells of KTx-patients are further
subdivided into CD56/16bright, CD56/16dim, and CD56/16low NK cells using the
histogram analysis of the CD16/CD56 PE-staining. NK cells were either
calculated as % NK cells of lymphocytes (left) or plotted as absolute NK cell
numbers per µl blood (right). (C) Gating strategy of the Trucount™ staining
procedure: CD45+ CD3− lymphocytes (left) were classified into CD56+ CD16+
NK cells and CD19+ B cells (middle). According to their PE-staining, CD56+
CD16+ NK cells were then further subgrouped into CD56/16bright (+++),
CD56/16dim, and CD56/16low NK cells (right). The box plots show median values
and the whiskers represent the 5–95 percentiles. Asterisks indicate the
p-values, * is defined as p≤0.05, ** as p≤0.01, and *** as p≤0.001.
the numbers but not the percentages of CD56/16dim NK cells
were slightly higher (p< 0.02) in the patient group with a kidney
graft for more than 12 months. Thus, long-term treatment with
immunosuppressive drugs for more than 1 year is not associated
with a manifestation of severe alterations in the NK cell repertoire.
When patients were grouped according to the presence of
DSA, non-organ-specific anti-HLA-antibodies (HLA+), or no
HLA antibodies (HLA−) in their serum, no significant differ-
ences could be observed in the percentage of NK cells in the
lymphocyte gate. However, patients with DSA had significantly
lower NK cell numbers compared to patients without any HLA
antibodies (Figure 2A). The discrimination into the CD16/CD56
density subsets revealed that only the number but not the percent-
age of CD56/16bright and CD56/16dim NK cells was significantly
decreased in patients with DSA (Figure 2B). Remarkably, the
presence of MICA-specific Abs in KTx-patients (n= 13) is not
associated with a significant modulation of the NK cell subset dis-
tribution (Figure 2C) suggesting that only antibodies against allo-
geneic HLA molecules of the current transplanted organ, i.e., DSA,
may have an impact on the peripheral NK repertoire. Whether this
decrease in FcγIII-positive NK cells in the periphery is associated
with a migration into the allogeneic kidney could not be addressed
in this cohort but will be analyzed in detail in future studies.
Since the DSA effect was observed in the CD56/16bright and
CD56/16dim NK subset, DSA seemed not to be linked to the
appearance of the CD56low NK subset in KTx-patients. Therefore,
patients were divided into immunosuppressive groups of CsA, Tac,
and combined Tac+ Sir (T/S) treatment. No significant differ-
ence between these groups could be observed regarding absolute
NK cell numbers but the percentage of NK cells in the T/S group
was significantly lower than in the two other groups (p= 0.0376,
Figure 3A). In the T/S group, the percentage of CD56/16dim NK
cells was significantly higher compared to the Tac group and the
percentage of the CD56/16low NK cells was significantly lower in
the T/S group compared to the CsA and Tac groups (Figure 3B).
Since CD56/16low NK cells are not detectable in healthy donors
(data not shown), CsA and Tac seem to be responsible for the
appearance of this new CD56/16low NK subset and the addition of
an mTOR inhibitor seems to counterbalance this effect. In terms
of absolute NK cell numbers, the tendency was the same but no
statistical significance could be reached (Figure 3C).
CsA AND Tac DIFFER IN THEIR EFFECT ON CD16+ CD6+ NK SUBSETS
AND THE EXPRESSION OF ACTIVATION MARKERS
These differential effects of CsA vs. Tac and T/S on NK cell sub-
sets became even more pronounced in detailed NK subset analyses
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FIGURE 2 | Natural killer cell numbers correlate with the
presence of DSA but not with MICA antibodies in kidney
transplanted patients. Anti-HLA class I, class II, and MICA
antibodies were detected in sera of kidney transplanted patients
using the Luminex technology. Absolute NK cell numbers and % NK
cells of lymphocytes were measured using Trucount™ FACS staining
of patient blood samples. (A) Percent (left) or absolute number per µl
blood (right) of NK cells of patients with DSA, other HLA-specific or
no antibodies. (B) According to their CD56/CD16 PE-density, NK cells
of DSA positive (+) or negative (−) KTx-patients were grouped into
CD56/16bright, CD56/16dim, and CD56/16low NK cells and plotted either
as % of lymphocytes or as cell number per µl blood. (C) The same
analysis was performed with patients grouped according to the
presence of MICA-specific Ab.
using CD16, CD6, CD161, and CD94/NKG2A as NK subset, and
CD69, HLA-DR as activation markers. In the comparison of 18
KTx-patients and 21 healthy donors, KTx-patients displayed a sig-
nificant shift toward the CD56bright NK subset with increased
percentages of both CD16− as well as CD16+ CD56bright NK
cells. The KTx-patients showed significantly deceased amounts of
CD16+ and CD6+ CD56dim NK cells compared to healthy donors
in parallel to a significant increase in CD16− and CD6− CD56dim
NK cells (Figure 4A). The distribution of 18 patients into three
treatment groups clearly identified a treatment-related cause of
this down-regulation. Although all KTx patient groups are sig-
nificantly differed in their NK repertoire compared to healthy
individuals, the Tac-treated patient group showed the most sig-
nificant differences by decreased CD16+ and CD6+ CD56dim and
elevated CD16− and CD6− CD56dim NK cells (Figure 4B). Since
CD16 CD6 double-positive CD56dim NK cells represent the major
NK subset in peripheral blood, the same strong impact of Tac was
also observed for this subset. Treatment with Tac alone was also
strongly associated with increased CD16− CD6− CD56bright NK
cells (Figure 4C). Even at the very low level of <1.5% CD6+
CD56bright NK cells in healthy donors, Tac-treatment in KTx-
patients resulted a further decrease of this subset. Interestingly,
addition of the mTORi Sirolimus seemed to counterbalance the
Tac effect because the values of the T/S group were closer to the
CsA group.
The impact of initial immunosuppression directly at KTx could
be demonstrated exemplarily by one patient, marked as open circle
who was initially treated with CsA for 5 months and switched to
Tac for the next 7 months until the date of protocol biopsy and
blood withdrawal. Due to his actual immunosuppressive medica-
tion by Tac, the patient was assigned into the Tac group. However,
the values of his NK cell subsets followed rather the CsA than the
Tac pattern indicating that the initial CsA-based modulation of
the NK cell repertoire was continued even after the switch to Tac
for 7 months.
The detailed analysis of the activation markers CD69, HLA-
DR, and CD25 revealed that both CD69 and HLA-DR were
decreased on CD56dim NK cells in the Tac group compared to
the CsA group although only CD69 reached statistical significance
(Figures 5A,B). The opposite trend was observed with the T and
NK cell marker CD161 that was expressed by almost all NK cells in
the Tac group (Figure 5C) with the highest density on CD56bright
NK cells (data not shown). This elevated expression in the Tac
group compared to CsA and T/S groups was also detected for
the inhibitory heterodimer CD94/NKG2A (Figures 5D,E). Since
in healthy donors, virtually all NK cells, CD56bright NK cells in
particular, express CD94 and most of them the CD94/NKG2A het-
erodimer, the low amount of CD94/NKG2A expressing CD56dim
NK cells in the CsA group indicates that in parallel to the pheno-
typic alterations, the balance between activating and inhibitory
receptors is also influenced by the immunosuppressive treat-
ment. Despite high proportions of CD69 and HLA-DR positive
NK cells, CD25 was only detectable at very low levels on NK
cells of these KTx-patients with <3% positive cells. Therefore,
Frontiers in Immunology | NK Cell Biology February 2013 | Volume 4 | Article 46 | 6
Neudoerfl et al. NK cells in kidney transplantation
FIGURE 3 | Natural killer cell distribution of KTx-patients is influenced
by different immunosuppressive drugs. Kidney transplanted patients
were grouped according to the immunosuppressive regimen, i.e., CsA, Tac,
or combination of Tac+Sir (T/S) and the NK cell proportion of lymphocytes
as well as the number per µl blood was compared between the groups. (A)
Based on their CD16/CD56 PE-staining, NK cells were subdivided into
CD56/16+++, CD56/16dim, and CD56/16low NK cells and calculated as % of
lymphocytes (B) or absolute numbers per µl (C) for each treatment group.
it seems to be unlikely that the NK cells in KTx-patients have
undergone recent activation because this would be detectable by
CD25 co-expression.
These phenotypic analyses indicate that immunosuppression
with both CNI and mTORi promotes CD56bright NK cells and
causes a shift toward the CD16− CD6− CD56dim NK cell sub-
set. While CsA treatment seemed to be associated with higher
proportions of CD69+ HLA-DR+ NK cells and lower CD161,
CD94/NKG2A expression, Tac-treatment seemed to support an
opposite phenotype of CD161hi, CD94/NKG2Ahi, CD69lo, HLA-
DRlo NK cells.
CsA, Tac, AND mTOR INHIBITORS HAVE DIFFERENTIAL EFFECTS ON NK
CELL ACTIVATION, DEGRANULATION, PROLIFERATION, AND IFN-γ
SECRETION IN VITRO
Since the differences in NK cell repertoires between the treatment
groups were observed in patients at 3, 6, or 12 months after trans-
plantation, we wanted to investigate whether the effects of the
two CNI, the mTORi, and MMF are already detectable in vitro
after several hours or days. Therefore, we performed a number of
in vitro experiments with PBMC of healthy donors that were acti-
vated in the presence of the different immunosuppressive drugs,
i.e., CsA, Tac, the mTORi Sir and MMF, or the solvent DMSO,
respectively. NK cell activation after 4 day culture in the pres-
ence or absence of IL-2 (500 U/ml, 4 days) was analyzed under the
influence of the different immunosuppressive drugs (Figure 6).
In all donors (n= 4), CsA treatment without IL-2 stimulation
resulted in a stronger decrease in NK cells compared to Tac, Sir,
and MMF that affected primarily the CD16+ CD56dim and the
CD56bright NK cell subsets. The few remaining NK cells showed
a CD16+ CD56bright phenotype. Simultaneous stimulation with
IL-2 completely prevented this NK cell depletion which was par-
tially caused by induction of apoptosis (not shown). Differences
between the drugs became more obvious in the direct comparison
of the activation markers CD69 and CD25 (Figure 6B). In the
absence of IL-2 stimulation, treatment with Tac and Sir but not
CsA and MMF resulted in significantly reduced CD69 expression
on both CD56bright and CD56dim NK subsets. Following IL-2 stim-
ulation, almost all NK cells expressed CD69 after 4 days in medium
and DMSO control samples. However, treatment with CsA, Tac,
and Sir but not with MMF significantly inhibited the CD69 up-
regulation primarily on CD56dim NK cells (Figure 6B). The CD25
induction by IL-2 seems to involve different mechanisms because
in the absence of IL-2, CsA alone was able to mediate CD25-
expression on the few remaining CD56dim NK cells. Following
IL-2 stimulation, CsA, Tac, and Sir significantly prevented CD25
induction on CD56dim NK cells in contrast to MMF that had only
minor effects on both NK subsets (Figure 6C). Thus, simultane-
ous IL-2 receptor-mediated signals interfere with both inhibitor
classes, CNI and mTORi, but not with the metabolic inhibitor
MMF.
CD16-mediated degranulation was also significantly reduced
in the presence of CsA, Tac, and Sir without additional IL-2 stimu-
lation (Figure 7A). However, this inhibitory effect was completely
abrogated in the presence of IL-2 confirming previous observa-
tions on NK cell activation with two NK cell lines, NKL and NK92
(data not shown). In contrast to degranulation, NK cell prolif-
eration in response to K562 cells was not significantly reduced
upon treatment with CsA, Tac, and Sir for 48 h (Figure 7B). The
addition of MMF did neither affect degranulation nor prolifer-
ation of NK cells. After 96 h incubation, inhibition of NK cell
proliferation could not be detected anymore indicating that the
intrinsic cytokine production following K562-stimulation may
counterbalance the initial inhibitory effect of the drugs.
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FIGURE 4 | CD16 and CD6 expression on NK cells is influenced by
different immunosuppressive treatments or KTx-patients. NK cells
in PBMC of healthy donors (n=21, gray boxes) or KTx-patients (n=18,
white boxes) were analyzed by flow cytometry with individual staining
of CD56, CD16, and CD6. (A) The proportion of CD56bright and CD56dim
NK cells was compared between patients and healthy individuals. (B)
NK cells were subdivided into CD16+ and CD16− or CD6+ and CD6−
CD56dim NK cells and each subset was compared between patients and
healthy individuals. KTx-patients were further classified into three
groups regarding their immunosuppressive regimen: CsA, Tac, and
combination of Tac+Sir (T/S). (C) NK cells were subdivided into CD16+
and CD16− or CD6+ and CD6− CD56bright NK cells and each subset was
compared between patients and healthy individuals. KTx-patients were
further classified into three groups regarding their immunosuppressive
regimen: CsA, Tac, and combination of Tac+Sir (T/S). One patient was
initially treated with CsA for 5 months after KTx and then switched to
Tac for the following 7 months [(B,C), open circle]. (D) CD6/CD16
double-positive NK cells are calculated for each treatment group and
healthy individuals. The combined expression of the different markers is
given as percentages of all CD3− CD56+ NK cells. Each data point
indicates one donor, and median values with standard deviations are
depicted as black bars.
In order to demonstrate the influence of CNI and mTORi on
cytokine secretion, IFN-γ ELISpot assays were performed using
K562 target cells as stimulus in the absence of IL-2. A strong
inhibitory effect of CsA and Tac on IFN-γ secretion was observed
in all three donors although with some variation in the sensitivity
to the drugs (Figure 7C). The capability of Sir to reduce IFN-
γ secretion varied substantially between donors, ranging from
significant inhibition in donor 2 and 3 to basically no effect in
donor 1 suggesting a donor-specific involvement of the mTOR
signaling pathway in IFN-γ induction. In contrast, MMF treat-
ment of PBMC had no impact on IFN-γ secretion in all three
donors.
These striking differences between the two CNI regarding
NK cell phenotype and function indicate that their suppressive
mechanism in NK cells differs from the well-studied NFAT-based
suppressive effect in T cells. Moreover, IL-2 receptor-mediated
signals are able to override the suppressive effects of CNI and
mTORi, especially in effector functions like degranulation that
do not require transcriptional activity. In addition, CsA vs. Tac
may impinge on the peripheral NK cell repertoire by the down-
regulation of CD16, CD6, CD69, HLA-DR, and the simultane-
ous up-regulation of CD161, CD94/NKG2A which is likely to be
associated also with functional alterations.
DISCUSSION
In our first analyses of peripheral NK cells from kidney recipi-
ents between 1 and 261 months after transplantation, we could
demonstrate that the NK cell phenotype and repertoire differs
significantly from healthy individuals without kidney transplan-
tation and subsequent immunosuppressive treatment. The overall
representation of NK cells within the lymphocyte compartment
was not altered between KTx-patients in their first year after
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FIGURE 5 | Immunosuppressive drugs modulate expression of
CD69, HLA-DR, CD161, and CD94/NKG2A on CD56bright and
CD56dim NK cells in KTx-patients. KTx-patients (n=18) were
grouped according to immunosuppressive drugs (CsA, Tac, and T/S)
and the expression of several activation markers was analyzed on
total CD56+ NK cells and the CD56bright and CD56dim subsets,
respectively. CD69 and combined CD69/CD25-expression is shown
in (A), HLA-DR expression in (B), CD161 expression in (C), CD94
single expression in (D), and NKG2A single and CD94/NKG2A
heterodimer expression in (E). The single or combined expression of
these different markers is given as percentage of all CD3− CD56+
NK cells.
transplantation and later time points or compared to healthy
individuals. However, the presence of donor-specific anti-HLA
class I- and/or class II antibodies (DSA) in sera of KTx-patients
was associated with lower absolute numbers of CD56dim and
CD56bright NK cells in peripheral blood. The observation that
the presence of MICA-specific antibodies in patient sera did not
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FIGURE 6 | Natural killer cell activation is differentially modulated
by treatment with CsA,Tac, Sir, or MMF. PBMC of three or four
healthy donors were incubated for 4 days with or without 500 U/ml IL-2
in the presence CNI (CsA and Tac), mTORi (Sir), or mycophenolate
(MMF) at a concentration of 10µM, DMSO control solvent or medium.
The percentage of all NK cells (CD3−/CD56+) and of the major NK cell
subsets defined as CD16+/CD16− CD56dim and CD56bright (A) as well as
CD69+ (B) and CD25+ NK cells (C)were determined by flow cytometry.
Each data point indicates one donor, and the median values with
standard deviations are depicted as black bars.
correlate with decreased NK cell numbers supports the assump-
tion that donor-specificity represents a functional link between
DSA and NK cells presumably by a recruitment of CD16+ NK
cells into the graft and activation of ADCC mechanisms. DSA are
strongly associated with chronic humoral rejection, one of the
major causes for renal allograft dysfunction which is defined by a
triad of DSA, C4d complement deposition in peritubular capillar-
ies and transplant glomerulopathy (Farkash and Colvin, 2012).
Since the association between serum DSA and C4d-mediated
complement activation in kidney biopsies is imperfect, an involve-
ment of NK cells was recently postulated primarily on the basis
of animal models (Akiyoshi et al., 2012). In order to prove a
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FIGURE 7 | Natural killer cell degranulation, proliferation, and
IFN-γ production is differentially inhibited by CsA,Tac, Sir, or
MMF treatment and this effect is counterbalanced by IL-2. (A)
Resting (−IL-2, n=3) or 48 h pre-activated PBMC (500 U/ml IL-2,
n=2) of healthy donors were stimulated by plate bound CD16 Ab
in the presence of CsA, mTORi, or MMF (10µM), DMSO control
solvent or medium. Degranulation was measured after 4 h by
CD107a-staining of CD3− CD56+ NK cells. Baseline degranulation
with isotype Ab reached <5% of resting and <26% of IL-2
activated NK cells (data not shown). (B) eFluor 670 stained PBMC
of healthy donors (n= 4) were either cultured alone or in the
presence of irradiated K562 cells for 48 or 96 h in the presence of
the drugs as outlined in (A). NK cell proliferation was quantified by
gating on CD3− CD56+ NK cells and definition of dividing eFluor
670low NK cells. (C) PBMC of healthy donors (n=4) were
stimulated with K562 cells at E:T ratios of 1:1 or 3:1 for 24 h in the
presence of the drugs as outlined in (A). IFN-γ secretion was
determined by the ELISpot technique where the number of
IFN-γ-producing cells is defined as spot-forming cells counted by
CTL ELISpot reader.
direct involvement of NK cells in ABMR and renal dysfunc-
tion, it will be necessary to demonstrate the presence of CD16+
NK cells and their ADCC potential in kidney tissue. Expression
profiling of kidney biopsies identified patterns of NK-related
transcripts that were highly associated with DSA and ABMR
(Hidalgo et al., 2010, 2012). Although the presence of MICA-
specific antibodies was found to be associated with increased
frequency of graft loss in a large cohort of KTx-patients (Zou
et al., 2007), the role of MICA/B in renal transplantation is still
discussed controversially (Cox et al., 2011). In our small cohort,
no influence of MICA antibodies could be demonstrated on
number or distribution of peripheral NK cells. Since the MICA
receptor NKG2D is expressed by virtually all human NK cells
and CD8+ T cells and co-regulates cytokine production (Barber
and Sentman, 2011), MICA antibodies may also interfere with
T cells and, therefore, not promote alterations in the NK cell
repertoire.
Regarding the two major peripheral NK cell subsets, the
CD56/16bright NK cell subset was found to be overrepresented
significantly in KTx-patients. Using the Trucount technique, the
CD56/16dim population could be subdivided into the classical
CD56/16dim NK cells and a new CD56/16low subset characterized
by a remarkably low CD56 and CD16 density. In the CD56/16dim
NK cell compartment, the alterations were primarily associated
with a selective down-modulation of the Fcγ-RIII, CD16, and the
scavenger receptor CD6 that was previously shown to character-
ize the most prominent peripheral NK cell subset (Braun et al.,
2011). A transient decrease in CD16 expression on NK cells can
be observed during the degranulation process following trigger-
ing of CD16 itself or other activating receptors like NCR (own
unpublished observations). This degranulation-associated down-
modulation of CD16 in vitro is mediated by internalization as
well as by shedding via metalloproteases and hallmarks recently
activated NK cells (Mota et al., 2004). However, in HIV-patients,
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low expression of CD16 on CD56dim NK cells was shown to be
associated with impaired ADCC indicating that decreased CD16
levels may also be associated with a functionally exhausted sta-
tus of NK cells (Lichtfuss et al., 2011). In the context of stem
cell transplantation, down-modulation of CD16 and KIR on NK
cells following IL-2 or IL-15 stimulation in combination with
CsA was shown to be accompanied by increased NKp30 and
decreased NKp44 and NKG2D expression and reduced NFAT-
dephosphorylation and nuclear translocation (Wang et al., 2007).
In separated CD56dim and CD56bright NK cells of healthy donors,
stimulation by IL-2+ IL-15 was only weakly suppressed by CsA
compared to the mTORi rapamycin or MMF (Eissens et al., 2010).
This discrepancy to our results may be due to major experimen-
tal differences to our in vitro setting by NK cell separation, drug
dosage, and addition of IL-15 to the culture conditions. This
interpretation is supported by the finding that NK cell stimu-
lation by IL-12 or IL-18 in combination with CsA resulted in
increased IFN-γ production suggesting that the CsA effect on
NK cells may vary substantially according to the microenviron-
ment. The differences in the individual responses to CNI may
also be mediated by single-nucleotide polymorphisms (SNPs) that
have been shown to either influence T cell function directly like
a polymorphism in the IL-17 promoter (Espinoza et al., 2011) or
indirectly by polymorphic variants of transcription factors such
as the Foxo family (Hedrick et al., 2012). Since T and NK cells
share several signaling pathways for cytokines and chemokines,
these functionally relevant polymorphisms may also influence
NK cell activity and response to calcineurin or mTOR inhibitors,
respectively.
In AML-patients after SCT and GVHD treated with FK506
(Tac), NK cell activity in terms of cytotoxicity, cytokine secre-
tion, and proliferation was found to be impaired. In addition,
expression of NKG2D, CD48, and DNAM-1 as well as cluster-
ing of adhesion molecules such as CD2, CD58, and CD49d was
found to be reduced (Kim et al., 2010). Since no alteration of
DNAM-1 expression on NK cells could be observed in our kid-
ney transplanted patient cohort (data not shown), it can be
assumed that the disease context has substantial influence on
the sensitivity of NK cell receptors toward immunosuppressive
drugs. A dose- and time-dependent effect of CsA and Tac was
demonstrated for KTx-patients whereby impaired NK activity
coincided with increased viral infection (Morteau et al., 2010).
Moreover, this study showed that conditioning of kidney recip-
ients with alemtuzumab (anti-CD52) had only weak effects on
NK cell distribution while basiliximab (anti-CD25) treatment
is associated with alterations of the CD56dim/CD56bright ratio.
These findings support our observation that NK cells are sen-
sitive to treatment with CNI even in different diseases. Never-
theless, the complex receptor expression and regulation of NK
cells generates a lot of variables that have to be taken into
account.
In our setting, detailed analyses of activation markers like
CD25, CD69, and HLA-DR and NK receptors like CD161 and
CD94/NKG2A revealed significant differences in these subsets
indicating that the quality of the immunosuppressive treatment
represented by different CNI and mTORi can impinge on the
distribution of NK cell repertoires in peripheral blood. The differ-
ent NK cell patterns with lower numbers of CD16+ and CD6+
CD56dim NK cells and elevated CD16− and CD6− CD56dim
NK cells as well as CD6− CD56bright NK cell subsets under
Tac-treatment may also reflect a different activation status of
NK cells in this pharmacological constellation which may be
due to a different availability of co-medication of immuno-
suppressive agents. For example, MMF undergoes an elevated
enterohepatic circulation leading to higher mycophenolic acid
(MPA) drug levels in combination with Tac whereas this effect
is lacking in combination with CsA (Brown et al., 2002). Thus,
it may be also possible that decreased activity of the inositol-
mono-phosphate-dehydrogenase under combined therapy with
Tac/MMF directly affects certain activation markers on NK cells,
a phenomenon that was not studied so far (Devyatko et al.,
2008).
Classical CNI, CsA, and Tac, both affect the NFAT-pathway by
binding either to cyclophilin or to FKB12 and inhibiting the phos-
phatase activity of calcineurin which leads to prevention from
dephosphorylation of the transcription factor NFAT, its nuclear
translocation and NFAT-driven gene expression of IL-2, IFN-γ,
GM-CSF, and others. In contrast, the involvement of the mTOR
pathway is currently intensively for regulatory T cells (Treg) in
comparison to effector T cells (Kim et al., 2010). While both path-
ways were studied primarily in T cells as primary target cells of
CNI, only limited information was available regarding the effect
of CNI vs. a combination with mTORi on the composition of NK
cell subsets in patients after kidney transplantation. The obser-
vation that one patient who was initially treated with CsA for
5 months and “switched” later on to Tac due to a mild biopsy-
proven rejection episode had maintained his initial CsA-driven NK
cell pattern suggests that the onset of immunosuppression deter-
mines the alteration in the NK cell repertoire even when another
CNI is applied afterward for months. This manifestation could be
mediated by similar mechanisms involved also in Th1/Th2 dif-
ferentiation like epigenetic regulation by promoter methylation
or regulation of transcription factors, for instance (Lawson et al.,
2012).
In summary, we could demonstrate that the type of immuno-
suppression has significant impact on the peripheral NK cell
repertoire of kidney transplant recipients. This observation adds
some novel aspects to the published studies on NK cell phenotype
and function in the context of stem cell and organ transplantation
showing that immunosuppressive drugs also affect NK cells at
various levels. Substantial differences between stem cell and organ
transplantation can be observed with respect to alterations in the
composition of NK cell subsets or effector functions such as cyto-
toxicity, proliferation, and cytokine secretion under the influence
of immunosuppression. This variability indicates an important
role of the clinical context for the efficacy of immunosuppression
on NK cells in peripheral blood. At least for kidney transplanta-
tion, the peripheral NK cell repertoire may represent an important
hallmark of immunosuppression and NK cells may even be useful
as sensors for a guided adjustment of immunosuppression in the
future. However, the relevance of NK cells for the local immune
response in the grafted tissue needs to be explored in future studies
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with biopsy material in addition to peripheral blood of kidney
recipients.
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